|
시장보고서
상품코드
2053002
편두통 치료제 시장 : 치료법별, 투여 경로별, 지역별 - 시장 규모, 점유율, 전망 및 기회 분석(2025-2032년)Migraine Therapeutic Market, By Therapeutics, By Route of Administration, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032 |
||||||
편두통 치료제 시장은 2026년에 75억 1,540만 달러로 추정되며, 2033년까지 143억 6,810만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 9.7%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 75억 1,540만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 9.70% | 2033년 시장 규모 예측: | 143억 6,810만 달러 |
편두통은 머리의 특정 부위에 심한 욱신거리는 통증이 발생하는 신경질환입니다. 통증은 편측성으로 나타나며, 맥박이 뛰는 성질을 가지고 있고, 신체 활동에 의해 악화되는 경향이 있습니다. 편두통은 메스꺼움이나 시각 장애와 같은 다른 징후와 증상을 유발하는 경향이 있는 두통의 일종입니다. 편두통의 근본적인 치료법은 아직 없지만, 약물 치료를 통해 발작의 예방과 억제, 혹은 증상의 악화를 막을 수 있습니다.
시장 역학
편두통의 유병률 증가, 안전하고 효과적인 치료법에 대한 수요 증가, 편두통과 그 치료 옵션에 대한 인식 개선, 세계 연구 및 개발 활성화는 예측 기간 동안 세계 편두통 치료제 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다. 예를 들어, 편두통은 삶의 질에 심각한 영향을 미치는 심각하고 흔한 신경 질환입니다. 2021년 세계보건기구(WHO)는 편두통을 장애로 인한 건강 조정 수명년(DALY) 손실이 가장 큰 신경질환으로 꼽았습니다.
2022년 2월, Biohaven Pharmaceutical Holding Company Ltd.와 Pfizer Inc.는 유럽의약품청(EMA)의 인체용 의약품 위원회가 리메게판트에 대해 긍정적인 견해를 채택했다고 보고했습니다. 리메게판트 75mg 용량(경구붕해정)은 성인의 전조증상을 동반하거나 동반하지 않는 편두통의 급성 치료와 한 달에 최소 4회 이상 편두통 발작이 있는 성인의 발작성 편두통 예방 치료 모두에 대해 시판 허가를 권고하고 있습니다.
본 조사의 주요 특징
- 이 조사는 다양한 부문의 잠재적 수익 창출 기회를 밝히고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 기업의 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 편두통 치료제 시장의 주요 기업 프로파일을 작성했습니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 세계 편두통 치료제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 편두통 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 편두통 치료제 시장 : 치료법별, 2021-2033년
제5장 세계의 편두통 치료제 시장 : 투여 경로별, 2021-2033년
제6장 세계의 편두통 치료제 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSM 26.06.17Migraine Therapeutic Market is estimated to be valued at USD 7,515.4 Mn in 2026 and is expected to reach USD 14,368.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 7,515.4 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.70% | 2033 Value Projection: | USD 14,368.1 Mn |
Migraine is a neurological disorder often described as intense pulsing or throbbing pain in one area of the head. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. Migraines are a type of headache that tend to cause other signs and symptoms, too, such as nausea and vision problems. There's no cure for migraines yet, but medicines can help prevent or stop them, or keep signs and symptoms from getting worse.
Market Dynamics
Increase in prevalence of migraine, increase in demand for safe and effective treatment, increase in awareness about migraine and its treatment options, and rise in research and development across the world are major factors expected to propel the growth of the global migraine therapeutic market during the forecast period. For instance, migraine is a serious and common neurological condition with a serious impact on quality of life. In 2021, migraine has been ranked by WHO as the most prevalent neurological condition causing the highest loss of years due to disability.
In February 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant. It is recommended as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global migraine therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer Inc., Novartis International AG, Merck & Co. Inc., GlaxoSmithKline PLC, Eli Lilly and Company, AstraZeneca PLC, Amgen Inc., Allergan Inc., Bausch Health Companies Inc., and Teva Pharmaceutical Industries Ltd., among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global migraine therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global migraine therapeutic market.
Market Segmentation
- Global Migraine Therapeutic Market, By Therapeutics (Revenue, USD Mn, 2021 - 2033)
- Pain-relieving Medications
- Preventive Medications
- Global Migraine Therapeutic Market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
- Oral and Nasal
- Injection
- Global Migraine Therapeutic Market, By (Revenue, USD Mn, 2021 - 2033) Geography
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Pfizer Inc.
- Novartis International AG
- Merck & Co. Inc.
- GlaxoSmithKline PLC
- Eli Lilly and Company
- AstraZeneca PLC
- Amgen Inc.
- Allergan Inc.
- Bausch Health Companies Inc.
- Teva Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Therapeutics
- Market Snapshot, By Route of Administration
- Market Snapshot, By Geography
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increase in prevalence of migraine around the world
- Adverse effects of drugs and increasing undiagnosed cases
- Increase in demand for safe and effective treatment
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Migraine Therapeutic Market, By Therapeutics, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Pain-relieving Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Preventive Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
5. Global Migraine Therapeutic Market, By Route of Administration, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral and Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
6. Global Migraine Therapeutic Market, By Geography, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Country
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Country
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Country
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Country
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Country
- South Africa
- North Africa
- Central Africa
7. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis International AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co. Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allergan Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bausch Health Companies Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
8. Section
- Research Methodology
- About us
